Our BioTherapeutics Leadership
Sanjaya Singh, Ph.D., is Global Head, Janssen BioTherapeutics within Janssen Research & Development. Sanjaya is responsible for leading an organization focused on biotherapeutic research, discovery, toxicology, clinical pharmacology and strategic external collaboration. In this role, Sanjaya drives the strategy and overall vision to expand and apply the capabilities of Janssen Research & Development to the discovery and development of protein, peptide and cell-based therapeutics.
Sanjaya is an accomplished scientific and business leader with more than 25 years of industry and academic experience. Prior to joining Johnson & Johnson, Sanjaya spent nine years at Boehringer Ingelheim, most recently serving as Vice President, Biotherapeutics Discovery. During his tenure, Sanjaya led a global team responsible for building a competitive and productive pre-clinical and clinical biotherapeutics pipeline. He has successfully led the identification of therapeutic targets in the field of immunomodulation and has developed biologic molecules in the fields of immunology, oncology, ophthalmology, cardio-metabolic and infectious disease.
In the realm of academia, Sanjaya held a faculty position in the Department of Molecular Biology at the Institute of Life Sciences in India. An author of numerous peer-reviewed articles, Sanjaya also is co-author on more than 25 patents.
Sanjaya earned a Ph.D. in Molecular Biology from Banaras Hindu University, Varanasi, Uttar Pradesh, India. He served as a Postdoctoral Fellow in the Department of Molecular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, and as a Research Associate in the Department of Biochemistry and Molecular Biology, also at MD Anderson Cancer Center in Texas.
SANJAYA SINGH, Ph.D.
Global Head, Janssen BioTherapeutics
Timothy Coogan, Ph.D., DABT, is Vice President of Biologics Toxicology, Janssen BioTherapeutics within Janssen Research & Development. In his role, Timothy leads a group responsible for designing, implementing and interpreting data from nonclinical safety/toxicology programs to support human clinical dosing and registration of therapeutic biologic and biopharmaceutical products. Timothy’s group is also responsible for conducting investigative studies addressing target- and biologic-specific issues during development.
Timothy has been with the Janssen Pharmaceutical Companies of Johnson & Johnson for more than 20 years, first joining the company as a Senior Scientist within the Drug Safety Evaluation group. With experience in both small and large molecule therapeutics, Timothy has contributed to or guided the nonclinical development of a number of leading marketed drugs. Timothy is also Head of the Preclinical Pediatric Team – a global group focused on providing guidance on nonclinical support for therapeutics to be used in pediatric populations. He has written a number of articles and book chapters on nonclinical support in pediatric drug development from this experience.
Timothy is a full member of the Society of Toxicology and Past-President of the Mid-Atlantic Chapter of the Society of Toxicology. He is also an Adjunct Assistant Professor in the School of Pharmacy at Temple University in Pennsylvania and Board Certified in Toxicology.
Dr. Coogan received his B.S. in Biology from Drexel University and earned his Ph.D. in Pharmacology from the University of the Sciences in Philadelphia.
Timothy P. Coogan, Ph.D., DABT
Vice President, Biologics Toxicology, Janssen BioTherapeutics
Hugh Davis, Ph.D., Vice President of Biologics Development Sciences, Janssen BioTherapeutics within Janssen Research & Development. In his role, Hugh leads the team responsible for pharmacokinetics (PK) bioanalysis, immune response assessment and research, and PK modeling and simulation.
Hugh has been with the Janssen Pharmaceutical Companies of Johnson & Johnson for more than 13 years, first joining the company as Director of Clinical Pharmacology. Prior to joining Johnson & Johnson, Hugh served as Global Head of the Pharmacodynamics and Exploratory Research Laboratory (PERL) at GlaxoSmithKline, where he led a team devoted to the development and validation of pharmacodynamics biomarker assays to be used in the evaluation of compounds.
With more than 25 years of experience in the pharmaceutical and biotechnology industries, Hugh has been an author on numerous scientific publications and has served as a reviewer for The British Journal of Pharmacology and Clinical Pharmacology and Therapeutics. Hugh has also led professorship positions at several academic institutions in the Philadelphia, Pennsylvania area including Villanova University, Thomas Jefferson University and Immaculata University.
Hugh earned his B.S. in Chemistry from Gannon University in Erie, Pennsylvania, and his M.S. and Ph.D. in Biochemistry from Villanova University.
Hugh M. Davis, Ph.D.
Vice President, Biologics Development Sciences, Janssen BioTherapeutics
Barry Springer, Ph.D., is Vice President, Strategy Technology and Innovation and Interim Head, Biologics research within Janssen Biotherapeutics. Barry is responsible for driving the coordination of strategic initiatives for the organization and leading scientific business partnering efforts. He helps to forge internal and external collaborations, including more robust interactions among large and small molecule research activities and technology platforms. In his 10+ years within Janssen, Barry has helped identify and establish strategic external partnerships for pharmaceutical and biologics discovery research.
With more than 23 years of experience in drug discovery and development, Barry’s expertise spans both small and large molecule discovery and development. Prior to joining the Janssen Pharmaceutical Companies of Johnson & Johnson, Barry spent seven years with 3-Dimensional Pharmaceuticals in multiple roles, most recently as Executive Director of Macromolecular Sciences at the time of the organization’s acquisition by Johnson & Johnson. In this role, Barry was responsible for all drug discovery-enabling platforms and protein engineering, expression, purification and structural biology teams and programs, as well as the company’s integration into the Johnson & Johnson organization.
Barry has authored a number of publications in scientific journals and participated in numerous invited lectures. He has also been awarded multiple patents as well as National Institutes of Health and National Institutes of Standards and Technology research grants for his work in the field of biotechnology.
Barry earned a B.S. in Microbiology, an M.S. in Biology, and Ph.D. in Biochemistry, all from the University of Illinois. Barry was also a postdoctoral fellow in the Department of Chemistry at the University of California.
Barry Springer, Ph.D.
VICE PRESIDENT, STRATEGY, TECHNOLOGY AND INNOVATION, and INTERIM HEAD, BIOLOGICS RESEARCH, JANSSEN BIOTHERAPEUTICS
Robert Willenbucher, M.D., is responsible for the coordination of Cell Therapy efforts across Janssen Research & Development and leading a team devoted to evaluating cell-based therapeutics that address significant unmet medical needs. His leadership includes oversight of lead program, CNTO 2476, in retinal degeneration.
After spending a number of years practicing medicine, Robert began his industry career in 1998 with Otsuka America Pharmaceutical and joined Johnson & Johnson shortly thereafter in 1999. Since then, he has held a number of positions with increasing responsibility across the organization. Prior to assuming his current role, Robert led the Stem Cell Organization, which first began as the Stem Cell Internal Venture (SCIV). In that role, he led the SCIV to successfully open an investigational new drug and initiate clinical development of CNTO 2476, which is now being developed within the Cell Therapy group.
In addition to his industry experience, Robert spent nine years in academia where he held faculty positions at the University of California, San Francisco and the University of California, Los Angeles.
Robert earned his M.D. from Columbia University College of Physicians and Surgeons, received an M.B.A. from The Wharton School of Business at the University of Pennsylvania and is a board certified internist and gastroenterologist.